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Abstract 23 
To identify molecular interactions between hepatitis B virus (HBV) and hepatitis delta 24 
virus (HDV), HBV sequences were analyzed in HBV/HDV-infected patients. 25 
Characteristic amino acid substitutions were found in cytosolic domains of HBsAg, in 26 
contrast to HBV mono-infected controls. The functional impact of HDV on replication 27 
of wild-type and mutant HBV was assessed in vitro. HDV co-transfection significantly 28 
reduced replication of HBV strains containing precore or basal core promoter 29 
mutations, while HBV polymerase or surface antigen mutants affected HDV 30 
replication in vitro. Conclusively, our study revealed distinct HBsAg mutational 31 
patterns in HBV/HDV-infected patients and novel functional interactions between 32 
HBV and HDV. 33 
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Hepatitis D virus (HDV) co- or super-infection in hepatitis B virus (HBV) infected 37 
individuals is the most severe form of chronic hepatitis. Although HBV-DNA is 38 
oftentimes suppressed in co-infected patients, fluctuating or persistently high levels of 39 
HBV viremia occur in delta hepatitis [1, 2]. We recently reported the distinct 40 
mutational pattern in the HDV genome from a nationwide Iranian cohort, where the 41 
prevalence of HDV is high [3]. We now analyzed the impact of HDV infection on the 42 
genomic sequences and functional properties of HBV in double-infected individuals. 43 
We studied HBV sequences of S-HBsAg, reverse transcriptase (rt), transcription 44 
regulators (including EnhI, EnhII and BOX-β), basal core promoter (BCP) and 45 
precore (PC) domains from HBV/HDV-infected patients with amplified HBV-DNA in a 46 
case-control setting. For each case with amplified HBV in HBV/HDV-infected 47 
patients, two HBV-mono-infected patients matched for sex, age, genotype and 48 
HBeAg status were studied as controls. The HBV/HDV infected patients more 49 
frequently had cirrhosis, while their HBV-DNA levels were lower than in HBV mono-50 
infected individuals (Table 1). Due to reduced HBV-DNA levels in HDV-infected 51 
individuals [1], HBV amplification yielded 17 nucleotide sequences for rt/HBsAg and 52 
EnhI and 9 sequences for EnhII, Box-β and BCP domains from the total cohort of 71 53 
HBV/HDV infected patients.  54 
To identify hot spots for HDV-driven HBV mutations, the number of non-55 
synonymous and synonymous substitutions per site (dN/dS) for each codon of 56 
HBsAg and rt domains was calculated. This analysis revealed a trend towards 57 
positive selection of amino acids (increased dN/ds ratio) at cytosolic loop (CYL)-I (for 58 
case group) and CYL-II (for case and control groups) of HBsAg (Fig.1A), where 59 
interactions between  HBsAg and HDV ribonucleoprotein take place [4, 5]. 60 
 We also observed a high rate of amino acid changes in the RT1 (G, F), A and 61 
C domains of rt sequences in HBV/HDV-infected patients (Fig.1A). While mutations 62 
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in the C domain (overlapping with CYL-II in HBsAg) mainly occur in response to 63 
antiviral treatments, the RT1 and A changes are presumably related to HBV-RNA 64 
priming, packaging and dNTP/NTP discrimination [6, 7].  65 
The striking differences in HBsAg-CYLs/RT domains between HBV-mono- and 66 
HBV/HDV-infected patients in contrast to the conserved structure of the HBsAg 67 
antigenic loop in both groups strongly indicated functional effects of HDV on HBV 68 
replication. We thus comprehensively analyzed the impact of HDV cotransfection on 69 
clinically common HBV RT and HBsAg mutants using transient transfection of Huh7 70 
hepatoma cells by replication-competent constructs [8].  71 
In agreement with our previous reports [9, 10], lamivudine-resistant polymerase 72 
mutations (SM: rtM204I, DM: rtL180M+rtM204V), which also induce changes at CYL-73 
II of the overlapping HBsAg, as well as their combination with immune escape 74 
mutations (sG145R, sP120T), located in the Ag-loop of HBsAg, impaired HBV 75 
replication in vitro, as evidenced by intra- and extra-cellular levels of HBV-DNA 76 
(Fig.1B-C). Co-transfection with HDV had overall no major impact on the replication 77 
of HBV polymerase or immune escape mutants (Fig.1B-C), except for a reduction of 78 
intracellular HBV levels of rtM204I, an HBV mutation that potentially inhibits HDV 79 
encapsidation [4]. 80 
Nearly half of the HDV-infected patients showed two mutations in the HBV-81 
EnhI domain (Fig.2A, nucleotides 1131 and 1167). Interestingly, the interaction of 82 
HDAg with HBV-EnhI and EnhII may trans-repress HBV replication [11]. Therefore, 83 
the altered sequence of EnhI in these patients possibly protects HBV from 84 
suppressive effects of HDAg. Further studies are required to confirm the frequency of 85 
these mutations in HDV-infected patients and their role in HBV-HDV interactions.  86 
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Although all patients were HBeAg-negative, BCP mutations (A1762T/G1764A) 87 
were less frequent in HBV/HDV-infected compared to HBV-mono-infected patients 88 
(Fig.2A, 11% vs. 44%, respectively). These data are in line with previous studies 89 
indicating a low prevalence of PC and BCP mutations in HBV/HDV-infected patients 90 
[12-14]. On a functional level, BCP-containing mutants showed an increased HBV 91 
replication in vitro (Fig.2B-C), in agreement with previous studies [8]. On the 92 
contrary, co-transfection of HBV mutants with HDV significantly reduced the 93 
replication of PC- or BCP-mutant HBV constructs (Fig.2B-C). These data suggest 94 
inhibitory effects of HDV on HBV PC/BCP mutants. In line, low levels of HBV-DNA in 95 
both serum and liver of HDV-infected patients with BCP or PC mutations had been 96 
reported [12, 13, 15]. Due to the inhibitory binding of HDAg to HBV-Enh elements 97 
[11] and the trans-activation of HBV pre-S and S promoters by L-HDAg [16], it is 98 
possible that BCP and PC mutations provide new interaction sites for HDV proteins 99 
to bind and exert inhibitory effects, for example, by changing transcription factor 100 
binding. Moreover, BCP also affects the sequence of the overlapping HBx protein, 101 
which cross-talks with L-HDAg in co-infected cells [8, 17].   102 
Next, we studied the effects of different HBV mutations on the replication and 103 
secretion of HDV in vitro. Mutations in CYLs are considered unfavorable for HDV 104 
secretion or infectivity, but tolerable for HBV subviral particle formation; thus, HBV 105 
isolates with these mutations are probably selected, when HDV co-replicates [4, 5]. 106 
Our in vitro experiments indicated a significant decrease of intracellular HDV 107 
replication, but increase in HDV secretion in sG145R or sP120T HBsAg-mutations 108 
(Fig.2D-E). One explanation for this increase might be the cytoplasmic positioning of 109 
non-glycosylated-Ag loop of HBsAg molecules [18], which provides an interaction 110 
opportunity for HDV RNP [19]. Moreover, due to the proximity of sG145 and sP120 111 
with glycosylation sites of the S-protein, mutations at these residues may affect 112 
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lateral S-S interactions, which occur differently for HBV and HDV due to their particle 113 
sizes [20]. Notably, PC or BCP mutations did not impact HDV replication or secretion 114 
in vitro (Fig.2D-E). 115 
In conclusion, our study indicates different selective adaptations in the HBV 116 
genome induced by HDV, including amino acid changes at interaction sites with HDV 117 
and selection of wild-type PC and BCP domains, likely to escape inhibitory effects of 118 
HDV on its replication. However, additional factors such as enhanced immune 119 
clearance prompted by the dual infection or HDV-induced host cell factors, which 120 
interfere with viral replication, need to be considered [16]. Future studies should also 121 
include longitudinal analyses in order to unravel the evolution of alterations in the 122 
HBV genome in delta hepatitis patients. 123 
 124 
  125 
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 183 
Table 1. Demographic, clinical and virological data of the patients.  184 
 185 
From 71 studied patients with positive HDAg-antibody, 24 had detectable HBV-DNA 186 
in serum by real-time PCR. Of this group, 17 cases were successfully amplified and 187 
sequenced by in-house PCR. Each case of HBV/HDV-infected patients was matched 188 
with two control patients of HBV mono-infected individuals based on the age, sex, 189 
viral genotype and HBeAg negativity. Differences were considered significant, if the 190 
p-value was <0.05 (chi-square or Mann-Whitney U-test). IFN: interferon, NAs: 191 
nucleot(s)ide analogues, n.a.: not applicable, n.s.: not significant. 192 
  193 
 HBV 
control group 
HBV/HDV 
case group 
p-value 
Total patients n.a. 71 n.a. 
Enrolled patients 34 17 n.a. 
Female (%) / Male (%) 14 (41.1%) / 20 (58.8%) 7 (41.1%) / 10 (58.8%) n.s. 
Age  37.4 (17 to 54) 38.5 (18 to 58) n.s. 
Cirrhosis 14.7% 52.9% <0.001 
ALT [U/L], median (range) 49 (15 to 172) 48 (20 to 86) n.s. 
HBV viral load [copies/ml], 
median (range) 
6.8x10
5
 
(3.1x10
3 
-8.3x10
8
) 
4.6x10
3
 
(1.1x10
3 
-2.3x10
5
) 
<0.001 
HBeAg status negative negative n.s. 
Viral 
Genotype 
HBV D D n.s. 
HDV n.a. 1 n.a. 
Treatment 
(history) 
IFN 26% 23% n.s. 
NAs 
 
62% 59% n.s. 
no treatment 12% 18% n.s. 
10 
 
Figure legends 194 
Fig.1. HBV genome alterations in HBV/HDV infected patients and functional 195 
impact of HDV on the replication of HBV polymerase and envelope mutants. 196 
(A) Comparison of amino acid substitution rates (dN/dS) for the S-HBsAg and the rt 197 
domain between HBV mono-infected (control, black) and HBV/HDV infected (case, 198 
red) patients. (B-C) Huh7 human hepatoma cells were transiently transfected with 199 
replication-competent HBV plasmids (5µg, genotype A, subtype adw2). Compared to 200 
mono-transfection (S=single, dark gray), the effect of co-transfection with wild type 201 
HDV genotype-1 (1µg, D=double, light gray) on HBV replication was studied. 202 
Intracellular HBV progeny DNA levels (B, representative Southern Blot after 203 
immunoprecipitation for anti-HBc and statistics) and released HBV virions (C, 204 
representative Southern Blot and statistics) are shown. Results from n≥3 205 
independent experiments with n=2 biological duplicates each. DL: double-stranded 206 
linear form (3.2kb), DM: LAM-resistance double mutation (rtL180M+rtM204V), LAM: 207 
lamivudine, pBS: pBluescript (negative control), RC: relaxed circular form (4.0kb), 208 
SM: LAM-resistance single mutation (rtM204I), SS: HBV DNA full-length single-209 
stranded form (1.5kb), wt: wild type HBV. 210 
 211 
Fig.2. Frequency of mutations in HBV replication/transcription controlling 212 
elements, functional impact of HDV on the replication of HBV precore or basal 213 
core promoter containing mutants and effects of mutant HBV on HDV 214 
replication. 215 
(A) Comparison of HBV nucleotide changes between HBV- (control, dark blue) and 216 
HBV/HDV-infected (case, light blue) patients at HBV enhancer domains (Enh I, II) 217 
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and transcription control motifs (BOX β, BCP and PC). ‘n’ represents the number of 218 
the patients included in the analyses. (B-E) Huh7 human hepatoma cells were 219 
transiently transfected with replication-competent HBV plasmids (5µg, genotype A, 220 
subtype adw2) containing different mutations in conjunction with precore (PC) or 221 
basal core promoter (BCP) mutations. Compared to mono-transfection (S=single, 222 
dark gray), the effect of co-transfection with wild type HDV genotype-1 (1µg, 223 
D=double, light gray) on HBV replication was studied. Intracellular HBV progeny DNA 224 
levels (B, representative Southern Blot after immunoprecipitation for anti-HBc and 225 
statistics) and released HBV virions (C, representative Southern Blot and statistics) 226 
are shown. Intracellular HDV genomic RNA levels (D) and extracellular HDV RNA 227 
levels in the supernatant (E) of co-transfected cells were assessed by Northern Blot. 228 
Results from n≥3 independent experiments with n=2 biological duplicates each. DL: 229 
double-stranded linear form (3.2kb), DM: LAM-resistance double mutation 230 
(rtL180M+rtM204V), LAM: lamivudine, pBS: pBluescript (negative control), RC: 231 
relaxed circular form (4.0kb), SM: LAM-resistance single mutation (rtM204I), SS: 232 
HBV DNA full-length single-stranded form (1.5kb), wt: wild type HBV. 233 
  234 
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Figure 2 239 
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